ReviewAtherosclerosis plus2026
Microbial mechanisms in atherosclerosis: Revisiting the infectious hypothesis.
Review in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is traditionally viewed as a lipid-driven inflammatory disease; however, this model does not fully explain acute coronary events arising from non-obstructive lesions or the persistence of residual cardiovascular risk despite lipid-lowering therapy. Emerging evidence implicates infectious agents as contributors to plaque instability rather than primary initiators of disease. Epidemiological studies demonstrate temporal associations between infections and myocardial infarction, while molecular analyses have identified bacterial components within atherosclerotic plaques. Recent findings suggest that microorganisms exist within plaques as biofilms, structured communities embedded in an extracellular matrix that permits immune evasion and long-term persistence. Under host-derived physiological triggers, including inflammatory surges and metabolic stress, biofilm dispersion may expose bacterial products that amplify inflammation and contribute to plaque destabilization. This biofilm-centered framework complements the lipid-centric model by identifying microbial factors as amplifiers of plaque vulnerability. It also highlights potential diagnostic and therapeutic targets aimed at reducing residual inflammatory cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.